Private Capital Group LLC lifted its holdings in shares of Celgene Co. (NASDAQ:CELG) by 12.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,605 shares of the biopharmaceutical company’s stock after purchasing an additional 180 shares during the period. Private Capital Group LLC’s holdings in Celgene were worth $151,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Capital Management Corp VA acquired a new position in shares of Celgene during the first quarter worth $10,955,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in Celgene by 36.9% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 342,301 shares of the biopharmaceutical company’s stock valued at $21,938,000 after buying an additional 92,209 shares during the period. Tibra Equities Europe Ltd acquired a new position in Celgene in the first quarter valued at $6,396,000. Bell Asset Management Ltd lifted its holdings in Celgene by 13.7% in the fourth quarter. Bell Asset Management Ltd now owns 78,822 shares of the biopharmaceutical company’s stock valued at $5,052,000 after buying an additional 9,525 shares during the period. Finally, Global Trust Asset Management LLC lifted its holdings in Celgene by 212.3% in the first quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 3,098 shares during the period. Institutional investors own 74.47% of the company’s stock.
Shares of NASDAQ CELG opened at $94.22 on Monday. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $95.44. The stock has a market cap of $66.18 billion, a PE ratio of 12.38, a P/E/G ratio of 0.43 and a beta of 1.71. The company has a current ratio of 2.23, a quick ratio of 2.12 and a debt-to-equity ratio of 3.21.
Several equities analysts recently issued reports on CELG shares. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating in a report on Monday, December 31st. Cantor Fitzgerald restated a “buy” rating and issued a $100.00 target price on shares of Celgene in a report on Thursday, January 3rd. Leerink Swann lowered shares of Celgene from an “outperform” rating to a “market perform” rating in a report on Thursday, January 3rd. Canaccord Genuity lowered shares of Celgene from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. Finally, Wells Fargo & Co dropped their target price on shares of Celgene from $90.00 to $84.00 and set a “market perform” rating on the stock in a report on Thursday, January 3rd. Two equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $99.41.
In other news, Director James J. Loughlin sold 23,466 shares of the company’s stock in a transaction dated Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the transaction, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ernest Mario acquired 2,000 shares of the company’s stock in a transaction dated Tuesday, February 12th. The shares were bought at an average price of $89.99 per share, for a total transaction of $179,980.00. The disclosure for this purchase can be found here. 0.39% of the stock is currently owned by corporate insiders.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: Consumer Price Index (CPI)
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.